Retinitis Pigmentosa (Retinitis) – Pipeline Review, H1 2020

Global Markets Direct’s, ‘Retinitis Pigmentosa (Retinitis) – Pipeline Review, H1 2020’, provides an overview of the Retinitis Pigmentosa (Retinitis) pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Retinitis Pigmentosa (Retinitis), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Retinitis Pigmentosa (Retinitis) and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

– The report provides a snapshot of the global therapeutic landscape of Retinitis Pigmentosa (Retinitis)

– The report reviews pipeline therapeutics for Retinitis Pigmentosa (Retinitis) by companies and universities/research institutes based on information derived from company and industry-specific sources

– The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

– The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

– The report reviews key players involved Retinitis Pigmentosa (Retinitis) therapeutics and enlists all their major and minor projects

– The report assesses Retinitis Pigmentosa (Retinitis) therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

– The report summarizes all the dormant and discontinued pipeline projects

– The report reviews latest news related to pipeline therapeutics for Retinitis Pigmentosa (Retinitis)

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Identify and understand important and diverse types of therapeutics under development for Retinitis Pigmentosa (Retinitis)

- Identify potential new clients or partners in the target demographic

- Develop strategic initiatives by understanding the focus areas of leading companies

- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

- Devise corrective measures for pipeline projects by understanding Retinitis Pigmentosa (Retinitis) pipeline depth and focus of Indication therapeutics

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

4D Molecular Therapeutics Inc

Allegro Ophthalmics LLC

Allergan Ltd

Alpine Biotherapeutics Corp

Amgen Inc

Ankar Pharma SL

Applied Genetic Technologies Corp

Biogen Inc

Brighton Biotech Inc

Casebia Therapeutics

Copernicus Therapeutics Inc

Dompe Farmaceutici SpA

DTx Pharma Inc

Editas Medicine Inc

Emerald Organic Products Inc

Endogena Therapeutics Inc

EyePoint Pharmaceuticals Inc

Eyestem Research Pvt Ltd

Eyevensys SAS

GenSight Biologics SA

Grupo Ferrer Internacional SA

Horama SA

ID Pharma Co Ltd

IVERIC bio Inc

jCyte Inc

Kubota Vision Inc

Kyoto Drug Discovery & Development Co Ltd

Lineage Cell Therapeutics Inc

MeiraGTx Holdings Plc

MimeTech Srl

Miragen Therapeutics Inc

Mireca Medicines GmbH

NanoScope Technologies LLC

Nanovector srl

Novartis AG

Ocugen Inc

OiDE OptoEye Inc

OliX Pharmaceuticals Inc

ONL Therapeutics Inc

OptiKira LLC

Oxford BioMedica Plc

Precision Biosciences Inc

Profarma

ProQR Therapeutics NV

PYCTX Ltd

Recursion Pharmaceuticals Inc

ReNeuron Group Plc

Retinagenix LLC

Rznomics Inc

SanBio Company Limited

SparingVision SAS

Staidson BioPharma Inc

Sumitomo Dainippon Pharma Co Ltd

Wave Life Sciences Ltd

Table of Contents

Table of Contents

Introduction

Retinitis Pigmentosa (Retinitis) - Overview

Retinitis Pigmentosa (Retinitis) - Therapeutics Development

Retinitis Pigmentosa (Retinitis) - Therapeutics Assessment

Retinitis Pigmentosa (Retinitis) - Companies Involved in Therapeutics Development

Retinitis Pigmentosa (Retinitis) - Drug Profiles

Retinitis Pigmentosa (Retinitis) - Dormant Projects

Retinitis Pigmentosa (Retinitis) - Discontinued Products

Retinitis Pigmentosa (Retinitis) - Product Development Milestones

Appendix

List of Tables

List of Tables

Number of Products under Development for Retinitis Pigmentosa (Retinitis), H1 2020

Number of Products under Development by Companies, H1 2020

Number of Products under Development by Universities/Institutes, H1 2020

Products under Development by Companies, H1 2020

Products under Development by Universities/Institutes, H1 2020

Number of Products by Stage and Target, H1 2020

Number of Products by Stage and Target, H1 2020 (Contd..1), H1 2020

Number of Products by Stage and Mechanism of Action, H1 2020

Number of Products by Stage and Mechanism of Action, H1 2020 (Contd..1), H1 2020

Number of Products by Stage and Route of Administration, H1 2020

Number of Products by Stage and Molecule Type, H1 2020

Retinitis Pigmentosa (Retinitis) – Pipeline by 4D Molecular Therapeutics Inc, H1 2020

Retinitis Pigmentosa (Retinitis) – Pipeline by Allegro Ophthalmics LLC, H1 2020

Retinitis Pigmentosa (Retinitis) – Pipeline by Allergan Ltd, H1 2020

Retinitis Pigmentosa (Retinitis) – Pipeline by Alpine Biotherapeutics Corp, H1 2020

Retinitis Pigmentosa (Retinitis) – Pipeline by Amgen Inc, H1 2020

Retinitis Pigmentosa (Retinitis) – Pipeline by Ankar Pharma SL, H1 2020

Retinitis Pigmentosa (Retinitis) – Pipeline by Applied Genetic Technologies Corp, H1 2020

Retinitis Pigmentosa (Retinitis) – Pipeline by Biogen Inc, H1 2020

Retinitis Pigmentosa (Retinitis) – Pipeline by Brighton Biotech Inc, H1 2020

Retinitis Pigmentosa (Retinitis) – Pipeline by Casebia Therapeutics, H1 2020

Retinitis Pigmentosa (Retinitis) – Pipeline by Copernicus Therapeutics Inc, H1 2020

Retinitis Pigmentosa (Retinitis) – Pipeline by Dompe Farmaceutici SpA, H1 2020

Retinitis Pigmentosa (Retinitis) – Pipeline by DTx Pharma Inc, H1 2020

Retinitis Pigmentosa (Retinitis) – Pipeline by Editas Medicine Inc, H1 2020

Retinitis Pigmentosa (Retinitis) – Dormant Projects, H1 2020

Retinitis Pigmentosa (Retinitis) – Discontinued Products, H1 2020

List of Figures

List of Figures

Number of Products under Development for Retinitis Pigmentosa (Retinitis), H1 2020

Number of Products under Development by Companies, H1 2020

Number of Products under Development by Universities/Institutes, H1 2020

Number of Products by Top 10 Targets, H1 2020

Number of Products by Stage and Top 10 Targets, H1 2020

Number of Products by Top 10 Mechanism of Actions, H1 2020

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2020

Number of Products by Top 10 Routes of Administration, H1 2020

Number of Products by Stage and Top 10 Routes of Administration, H1 2020

Number of Products by Top 10 Molecule Types, H1 2020

Number of Products by Stage and Top 10 Molecule Types, H1 2020

    Pricing

Discounts available for multiple report purchases.

reportstore@globalmarketsdirect.com
+44 (0) 161 359 5414

Saved reports